FDA Panel Rejects Use of MDMA for Treatment of PTSD
Posted inAmerican Psychiatric Assn Drug Abuse and Traffic Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration Institute for Clinical and Economic Review Justice Department Lykos Therapeutics Medicine and Health Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Placebos Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Psychiatry and Psychiatrists Regulation and Deregulation of Industry Therapy and Rehabilitation Veterans your-feed-healthcare

FDA Panel Rejects Use of MDMA for Treatment of PTSD

An independent group of experts expressed concerns that the data from clinical trials did not outweigh risks for treatment of post-traumatic stress disorder.
FDA Panel Weights MDMA Therapy for PTSD
Posted inDrug Abuse and Traffic Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration Lykos Therapeutics Mental Health and Disorders Multidisciplinary Assn for Psychedelic Studies Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Regulation and Deregulation of Industry

FDA Panel Weights MDMA Therapy for PTSD

An independent group of experts is meeting Tuesday to consider whether to allow use of this illegal drug, also known as Ecstasy, to treat PTSD.
FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws
Posted inAlternative and Complementary Medicine American Psychiatric Assn Clinical Trials Depression (Mental) Drug Abuse and Traffic Drug Enforcement Administration Drugs (Pharmaceuticals) Ecstasy (Drug) Food and Drug Administration MAPS Public Benefit Corp Mental Health and Disorders Placebos Post-Traumatic Stress Disorder Psychedelic and Hallucinogenic Drugs Regulation and Deregulation of Industry Research Therapy and Rehabilitation Veterans

FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws

The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.